Charles Kwobah

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton, Joseph Musaazi, Cissy Kityo et al. · The Lancet HIV · 2022 · 131 citations · Full text

Barriers to implementing antimicrobial stewardship programs in three low- and middle-income country tertiary care settings: findings from a multi-site qualitative study

Robert Rolfe, Charles Kwobah, Florida Muro et al. · Antimicrobial Resistance and Infection Control · 2021 · 82 citations · Full text

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Cissy Kityo, Immaculate Nankya et al. · The Lancet HIV · 2017 · 79 citations · Full text

Factors Associated with First-Line Antiretroviral Therapy Failure amongst HIV-Infected African Patients: A Case-Control Study

Charles Kwobah, Ann Mwangi, Julius Koech et al. · World Journal of AIDS · 2012 · 41 citations · Full text

Immunodeficiencies, Population Health Sciences, Western Kenya +24

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text